Programmed cell death protein 1 and receptor tyrosine kinase pathways (PD-1/RTK)

The combined PD-1 and Receptor Tyrosine Kinase (RTK) pathways represent a multi-modal therapeutic strategy aimed at enhancing anti-tumor immunity while simultaneously inhibiting tumor growth and angiogenesis [1]. Programmed cell death protein 1 (PD-1) is a key immune checkpoint receptor that limits T-cell activity to prevent autoimmunity, but is often exploited by tumors to evade immune surveillance [2]. Receptor Tyrosine Kinases, such as VEGFR, FGFR, and MET, are cell surface receptors that drive essential oncogenic processes including cell proliferation, survival, and the development of a pro-angiogenic, immunosuppressive tumor microenvironment [3]. By combining PD-1 inhibitors with RTK inhibitors, the therapy aims to reverse T-cell exhaustion and improve the infiltration of effector cells into the tumor [4]. RTK inhibition specifically helps to normalize tumor vasculature and reduce the presence of immunosuppressive cells like myeloid-derived suppressor cells and regulatory T cells [5]. This dual-pathway approach has become a standard of care for several advanced malignancies, including renal cell carcinoma and endometrial cancer [6]. Clinical evidence suggests that the combination can overcome resistance to single-agent immunotherapy by modulating the tumor's physical and chemical landscape [1, 4]. However, the use of these combined agents requires careful clinical monitoring due to the potential for overlapping toxicities from both immune-mediated mechanisms and kinase inhibition [6].

Other names

PD-1/VEGFR combinationImmune checkpoint and tyrosine kinase inhibitor combinationPD-1/RTK axisPD-1/TKI combination

Simultaneous blockade of the PD-1/PD-L1 immune checkpoint to restore T-cell activity and inhibition of receptor tyrosine kinases to disrupt pro-tumorigenic signaling, angiogenesis, and the immunosuppressive tumor microenvironment.